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LETTERS TO THE EDITORPATIENTS WITH CANCER
AND CENTRAL PULMONARY
EMBOLI TREATED
SURGICALLY
To the Editor:
We read with great interest the recent
article by Greelish and colleagues,1
‘‘Improved Midterm Outcomes for
Type A (Central) Pulmonary Emboli
Treated Surgically,’’ which has the po-
tential to change the landscape of indi-
cations for surgical intervention in
acute central pulmonary embolism.
The volume of acute pulmonary embo-
lectomy cases completed at our institu-
tion would significantly increase if we
used the treatment algorithm proposed.
Specifically, we refer to the algorithm
for patients without the classic indica-
tions for surgical intervention and
moderate to severe right ventricular dys-
function according to 2-dimensional
echocardiography. Currently at the Ot-
tawa Heart Institute, our patients under-
going acute pulmonary embolectomy
patients are limited to those in extremis
with the classic indications outlined in
by Greelish and colleagues,1 with resul-
tant poor survival outcomes overall. If
our indications for surgical intervention
were tobebroadened to includeall those
with a central pulmonary embolism and
moderate to severe right ventricular dys-
function, by expanding the scope of care
for this critically ill group an important
associated cost burden would be placed
on our already limited operating room
and surgical intensive care unit
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The JournalIn light of the potential increase
in surgical volume and associated
resource use cost, we consider it im-
portant to eliminate additional con-
founders from the survival analysis.
In particular the differences between
the medical and surgical management
groups with respect to history of can-
cer must be reexamined. It would be
of great value to complete Kaplan-
Meier life table analysis for both
groups, excluding all patients with can-
cer from analysis. Active malignancy
is an important confounder for all
cause death rates and subsequent life
table analysis. The presence of active
or incurable cancer would certainly in-
fluence patient management in both
subtle and overt ways, the most overt
way being that a patient with meta-
static or locally advanced cancer in
less likely to be considered for aggres-
sive surgical management. An addi-
tional important point is that
regardless of whether patients with
cancer die directly of their disease,
the very presence of malignancy puts
them at risk for death from other asso-
ciated conditions, including thrombo-
embolism, infection, myocardial
infarction, hemorrhage, and stroke.2-4
We understand it was stated that
only 1 patient in the surgical treat-
ment group and 23 in the medically
treated group died of cancer.1 We
still recommend that the survival
analysis be completed to exclude
this confounding group, however,
because the presence of cancer
influences patient management and
puts patients at risk for death
from other malignancy associated
conditions.2-4
We anticipate with great interest the
results from the survival analysis
excluding patients with cancer. If
there is still a survival difference
evident after exclusion of patients
with cancer, Greelish and colleagues’
article1 truly has the potential to
change the scope of surgery for acute
pulmonary embolectomy by broaden-
ing our indications for surgical
management.of Thoracic and Cardiovascular SurgeAnna L. McGuire, MDa
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We appreciate the comments of
McGuire and Rubens on our article
regarding the proposed new algorithm
for surgical management of central
surgically accessible (Vanderbilt type
A) pulmonary embolism. In our arti-
cle,1 we documented that active ma-
lignancy was a confounding variable
for survival. Certainly, in a patient
with metastatic cancer or locally ad-
vanced malignancy, the decision to
proceed with aggressive surgical man-
agement should be undertaken only
after careful consideration. In our
study, among patients treated surgi-
cally, 2 had active malignancy and 1
died during follow-up as a result of
the cancer. In the medically treated
group, the incidence of cancer at the
time of diagnosis of pulmonary embo-
lism was higher but not significantly
so (32% vs 13%; P ¼ .135). Had
we excluded all patients with a diagno-
sis of cancer at the time of diagnosis of
pulmonary embolism, we would have
excluded 34 patients (32 in the medi-
cal group and 2 in the surgical group),
leaving for analysis a very smallry c Volume 144, Number 3 735
Letters to the Editornumber of patients, especially in the
surgical group (n ¼ 13).
Exclusion of patients with cancer
at the time of pulmonary embolism,
however, is more complicated than
performing a Kaplan-Meier survival
analysis with fewer patients at
follow-up. There are several different
types of cancer, of course, and the
survival and prognosis are influenced
not only by the type of cancer (Hodg-
kin lymphoma vs pancreatic cancer
for example) but also by the staging
(localized vs metastatic), the overall
condition of the patient, and the pa-
tient’s age. We agree with McGuire
and Rubens that a patient with meta-
static cancer will likely have a very
poor prognosis and probably should
not undergo aggressive surgery for
pulmonary embolism, and this is an
assessment that should be performed
by the surgeon, the patient, and the
family at the bedside. If, however,
a patient has a history of cancer that
has been treated successfully with
surgery, chemotherapy, or radiation
therapy and as a result has a meaning-
ful survival (>1 year), then surgery
for pulmonary embolism should be
carefully considered. In general, for
patients with known diagnosis of can-
cer at the time of pulmonary embo-
lism, our practice is to consult our
medical oncology colleagues, when
patient stability makes this feasible,
to give us an assessment of the esti-
mated survival. If survival is esti-
mated at greater than 1 year, we
consider pulmonary embolism sur-
gery and go over this with the patient
and family.
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FOR ANTERIOR LEAFLET
PROLAPSE
To the Editor:
The publication by Zannis and col-
leagues1 highlights the critically im-
portant new surgical approach for the
treatment of anterior leaflet prolapse.
Konstantinos and colleagues per-
formed the parachute technique on
44 consecutive patients.1 Echocardio-
graphic examination was performed
in all patients to measure the distance
from the tip of each papillary muscle
to the annular plane at end systole in
an apical view. Constructing the para-
chute according to the described dis-
tance may cause the persistence of
prolapse because there must be coap-
tation depth between the anterior and
posterior leaflets.2 The coaptation
depth is approximately 4 mm in the
anterior and posterior commissures
and approximately 8 mm between
the A2 and P2 scallops. Adjusting
the coaptation depth is not clear in
the article.
Furthermore, the authors did not
mention the causes of the patient’s dis-
ease. The artificial chordal replacement
can be used in both Barlow’s disease
and fibroelastic deficiency.3 Nonethe-
less, Barlow’s disease has distinct fea-
tures. It generally has complex valve
pathology and dysfunction, which is
most often multisegmental. Lesions in-
clude excessively thick and billowing
leaflet segments, chordal elongation
and chordal rupture, calcification of
the papillary muscles or annulus with
chordae restriction, and severe annular
dilatation with giant valve size.4
Patients with fibroelastic deficiency
often present withminimal, as opposed
to excess, tissue, so extensive leaflet
resection or complex leaflet remodel-
ing procedures are rarely indicated.4
All lesions present should be corrected
to store not only valve competency but
also a normal valve geometry and satis-
factory line closure. Because excess
tissue is the hallmark lesion of Bar-
low’s disease, leaflet resection and
restoration of normal relationship ofardiovascular Surgery c September 201the annular dimension are usually cen-
tral to the surgical strategy.4,5 The
authors state that in the beginning of
their experience, large anterior mitral
leaflet prolapses had been addressed
by triangular resection of some of
the excess tissue before parachute
implantation. In the perennial concern
of simplification and standardization
of surgical techniques, they have
completely abandoned anterior mitral
leaflet triangular resection, and the
running suture was used to crimp
excessive tissue on the Dacron strip of
the parachute.1 However, crimping
may only remove the excess tissue ver-
tically, not horizontally. So performing
triangular resection in the anterior leaf-
let may improve the result in selected
cases.
This is an admirable study. The
readers thank the authors for sharing
their experience and knowledge. The
explanation of previously described
points will be helpful for better
understanding.
Murat Tavlasoglu, MD
Department of Cardiovascular
Surgery
Diyarbakir Military Medical Hospital
Diyarbakir, Turkey
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In this patient series,1 we report our
experience regarding the correction of2
